Title | TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, Hepworth MR, Van Voorhees AS, Comeau MR, Artis D |
Journal | Sci Transl Med |
Volume | 5 |
Issue | 170 |
Pagination | 170ra16 |
Date Published | 2013 Jan 30 |
ISSN | 1946-6242 |
Keywords | Adaptive Immunity, Animals, Cytokines, Dermatitis, Atopic, Disease Models, Animal, Humans, Immunity, Innate, Inflammation, Interleukins, Lymphocytes, Mice, Mice, Inbred C57BL, Protein Binding, Skin |
Abstract | Innate lymphoid cells (ILCs) are a recently identified family of heterogeneous immune cells that can be divided into three groups based on their differential developmental requirements and expression of effector cytokines. Among these, group 2 ILCs produce the type 2 cytokines interleukin-5 (IL-5) and IL-13 and promote type 2 inflammation in the lung and intestine. However, whether group 2 ILCs reside in the skin and contribute to skin inflammation has not been characterized. We identify a population of skin-resident group 2 ILCs present in healthy human skin that are enriched in lesional human skin from atopic dermatitis (AD) patients. Group 2 ILCs were also found in normal murine skin and were critical for the development of inflammation in a murine model of AD-like disease. Remarkably, in contrast to group 2 ILC responses in the intestine and lung, which are critically regulated by IL-33 and IL-25, group 2 ILC responses in the skin and skin-draining lymph nodes were independent of these canonical cytokines but were critically dependent on thymic stromal lymphopoietin (TSLP). Collectively, these results demonstrate an essential role for IL-33- and IL-25-independent group 2 ILCs in promoting skin inflammation. |
DOI | 10.1126/scitranslmed.3005374 |
Alternate Journal | Sci Transl Med |
PubMed ID | 23363980 |
PubMed Central ID | PMC3637661 |
Grant List | 2-P30 CA016520 / CA / NCI NIH HHS / United States 5-P30-AR-057217 / AR / NIAMS NIH HHS / United States AI061570 / AI / NIAID NIH HHS / United States AI074878 / AI / NIAID NIH HHS / United States AI083480 / AI / NIAID NIH HHS / United States AI085828 / AI / NIAID NIH HHS / United States AI087990 / AI / NIAID NIH HHS / United States AI095466 / AI / NIAID NIH HHS / United States AI095608 / AI / NIAID NIH HHS / United States AI097333 / AI / NIAID NIH HHS / United States AI102942 / AI / NIAID NIH HHS / United States DP5 OD012116 / OD / NIH HHS / United States DP5OD012116 / OD / NIH HHS / United States KL2 TR000139 / TR / NCATS NIH HHS / United States KL2-RR024132 / RR / NCRR NIH HHS / United States KL2TR000139 / TR / NCATS NIH HHS / United States P30 AR057217 / AR / NIAMS NIH HHS / United States P30 CA016520 / CA / NCI NIH HHS / United States P30-DK050306 / DK / NIDDK NIH HHS / United States R01 AI061570 / AI / NIAID NIH HHS / United States R01 AI074878 / AI / NIAID NIH HHS / United States R01 AI095466 / AI / NIAID NIH HHS / United States R01 AI097333 / AI / NIAID NIH HHS / United States R01 AI102942 / AI / NIAID NIH HHS / United States R21 AI083480 / AI / NIAID NIH HHS / United States R21 AI087990 / AI / NIAID NIH HHS / United States T32 AI007532 / AI / NIAID NIH HHS / United States T32-AI007532 / AI / NIAID NIH HHS / United States U01 AI095608 / AI / NIAID NIH HHS / United States |
Submitted by alp2017 on May 20, 2015 - 10:32am